KRAS and cancer: Alternative therapeutic approaches include inhibiting the interaction of farnesylated KRAS with cGMP phosphodiesterase delta (PDEδ) using small molecule inhibitors including deltarasin; however, this approach is not selective for cancer cells and causes systemic toxicities [74].